At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. 

Our mission is to put the patient first through innovation and we do this thanks to our Australian invented Haemafrac®, Aegros' unique electroseparation process. 

Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma. 

Aegros is currently undertaking the final preparations for the submission of a dossier for the registration of this hyperimmune against Covid-19 on the Australian Register of Therapeutic Goods (ARTG)

Simultaneously, Aegros is finishing the upgrade of its existing hyperimmune facility at Macquarie Park NSW to be able to process 100,000l of plasma per year.


Aegros

Org chart

Similar companies